ChiCTR2500109004 版本V1.0 版本创建时间2025/09/10 11:06:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500109004 

最近更新日期:

Date of Last Refreshed on:

2025-09-10 11:06:43 

注册时间:

Date of Registration:

2025-09-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

直肠癌术前MRI评估肿瘤沉积与病理诊断的一致性及其预后价值研究

Public title:

Consistency of Preoperative MRI-Assessed Tumor Deposits with Pathological Diagnosis and Their Prognostic Significance in Rectal Cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

术前影像学评估结直肠癌肿瘤沉积(癌结节)与病理诊断一致性及预后价值研究

Scientific title:

Study on the Consistency between Preoperative Imaging Evaluation and Pathological Diagnosis of Tumor Deposits (Cancer Nodules) in Colorectal Cancer and Its Prognostic Value

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

欧阳凯博 

研究负责人:

钟敏儿 

Applicant:

Kaibo Ouyang 

Study leader:

Miner Zhong 

申请注册联系人电话:

Applicant telephone:

+86 136 7030 6116

研究负责人电话:

Study leader's telephone:

+86 137 1010 8605

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1173845653@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhongminer@gdph.org.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

南方医科大学附属广东省人民医院(广东省医学科学院),胃肠外科

研究负责人通讯地址:

南方医科大学附属广东省人民医院(广东省医学科学院),胃肠外科

Applicant address:

Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

Study leader's address:

Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学附属广东省人民医院(广东省医学科学院),胃肠外科

Applicant's institution:

Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

研究负责人所在单位:

南方医科大学附属广东省人民医院(广东省医学科学院),胃肠外科

Affiliation of the Leader:

Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2025-471-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省人民医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Guangdong Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-09 00:00:00

伦理委员会联系人:

张绪超

Contact Name of the ethic committee:

Xvchao Zhang

伦理委员会联系地址:

广东省人民医院

Contact Address of the ethic committee:

Guangdong Provincial People's Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 139 2602 7885

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学附属广东省人民医院(广东省医学科学院),胃肠外科

Primary sponsor:

Department of Gastrointestinal Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

研究实施负责(组长)单位地址:

广州市越秀区中山二路106号

Primary sponsor's address:

No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省人民医院

具体地址:

广州市越秀区中山二路106号

Institution
hospital:

Guangdong Provincial People's Hospital

Address:

No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou City

经费或物资来源:

广东省人民医院,全职引进人才启动经费,KY0120230009,融合多分子事件及肿瘤可视化影像的量化分析预测局部进展期直肠癌新辅助治疗敏感性

Source(s) of funding:

Guangdong Provincial People's Hospital, Start-up funds for full-time Talent Introduction, KY0120230009, quantitative analysis integrating multi-molecular events and tumor visualization images to predict the sensitivity of neoadjuvant therapy for locally advanced rectal cancer

Target disease:

Rectal cancer

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

主要目的:本研究拟建立一套直肠癌影像-病理结节一一对应方法,以病理诊断为金标准,前瞻性验证MRI诊断肿瘤沉积物(TDs)的准确性。 次要目的: 1. 分析TDs的MRI的影像特征,进而构建基于影像学特征的 TDs 诊断标准。 2. 明确影像学及病理诊断的TDs对局部复发、无病生存期和总体生存期的影响。 3. 评估病理学家之间以及放射科医生之间的观察者间一致性。 4. 基于病理金标准分析、验证MRI图像中鉴别 TDs 与 EMVI、淋巴结转移的方法。  

Objectives of Study:

Main Objective: This study aims to establish a one-to-one correspondence method between rectal cancer imaging and pathological nodules, using pathological diagnosis as the gold standard, and prospectively verify the accuracy of MRI in diagnosing tumor deposits (TDs). Secondary Objectives: 1. Analyze the MRI imaging features of TDs and construct a diagnostic standard for TDs based on imaging features. 2. Clarify the impact of imaging and pathological diagnosis of TDs on local recurrence, disease-free survival, and overall survival. 3. Evaluate the interobserver agreement between pathologists and radiologists. 4. Analyze and validate methods for distinguishing TDs from extramural vascular invasion (EMVI) and lymph node metastasis in MRI images based on the pathological gold standard.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄范围:患者年龄>=18 岁; 2. 经病理组织学诊断确诊为原发性直肠腺癌的患者; 3. 具有完整的盆腔MRI资料; 4. 接直肠癌切除手术的患者(包括术前接受治疗的患者); 5. 患者自愿参与本研究,并签署书面知情同意书,愿意配合随访。

Inclusion criteria

1. Age range: Patients must be >= 18 years old; 2. Diagnosed with primary rectal adenocarcinoma by pathological histology; 3. Possess complete pelvic MRI data; 4. Patients who have undergone rectal cancer resection surgery (including those who received treatment before surgery); 5. Patients volunteer to participate in this study, sign a written informed consent form, and agree to cooperate with follow-up.

排除标准:

1. 患者就诊时患有复发性肿瘤、同步性肿瘤、家族性腺瘤性息肉病或炎症性肠病; 2. 无法进行MRI或影像学资料图像质量差; 3. 具有任何可能影响方案依从性的疾病史(如严重精神障碍、认知功能障碍、药物滥用或成瘾等); 4. 妊娠或哺乳期妇女,或有生育能力且不愿/无法采取有效避孕措施者; 5. 检查前 6 个月内曾参加过任何药物临床试验者。

Exclusion criteria:

1. The patient was diagnosed with recurrent tumors, synchrony tumors, familial adenomatous polyposis or inflammatory bowel disease at the time of the visit. 2. MRI cannot be performed or the image quality of imaging data is poor; 3. Have any medical history that may affect compliance with the protocol (such as severe mental disorders, cognitive dysfunction, drug abuse or addiction, etc.); 4. Pregnant or lactating women, or those who are fertile but unwilling or unable to take effective contraceptive measures; 5. Those who have participated in any drug clinical trials within the six months prior to the examination.

研究实施时间:

Study execute time:

From 2025-03-01 00:00:00 To 2032-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-09-15 00:00:00 To 2027-12-31 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

组织病理学评估,即病理诊断:由2名病理学家通过光学显微镜对苏木精和伊红染色的组织载玻片评估CT所识别的结节是否为肿瘤沉积。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

The histopathological evaluation: two pathologists assess the nodules identified by CT through the use of an optical microscope on tissue slides stained with hematoxylin and eosin to determine if they are tumor deposits.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

利用术前MRI检查诊断直肠癌肿瘤沉积物

Index test:

Preoperative MRI scans to diagnose tumor deposits of patients with rectal cancer.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

年龄>=18 岁、经病理组织学诊断确诊为原发性直肠腺癌,且术前MRI发现直肠周围系膜含可疑结节的患者

例数:

Sample size:

340

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients aged 18 years or older, diagnosed with primary rectal adenocarcinoma by pathological histology, and found to have suspicious nodules in the perirectal mesentery on preoperative MRI.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

None

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

广东省人民医院 

单位级别:

三甲 

Institution
hospital:

Guangdong Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

准确率

指标类型:

主要指标

Outcome:

Accuracy rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

敏感度

指标类型:

主要指标

Outcome:

Sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异度

指标类型:

主要指标

Outcome:

Specificity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阳性预测值

指标类型:

主要指标

Outcome:

Positive predictive value

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴性预测值

指标类型:

主要指标

Outcome:

Negative predictive value

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ROC曲线

指标类型:

主要指标

Outcome:

Receiver Operating Characteristic (ROC) Curve

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

一致性程度

指标类型:

主要指标

Outcome:

Degree of consistency

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

1 年、3 年和 5 年生存率

指标类型:

次要指标

Outcome:

One-year, three-year and five-year survival rates

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

风险比估计

指标类型:

次要指标

Outcome:

Hazard Ratio (HR) Estimate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

结节

组织:

Sample Name:

Nodules

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

患者详细信息,包括人口统计学和临床特征,如确诊年龄、性别、肿瘤位置(高、中、低位直肠)以及术前癌胚抗原和 CA19-9 水平通过医院病历系统检索并收集。数据将通过使用医院系统内分配的唯一患者识别号进行匿名化。放射学和病理结果以及治疗数据也将被记录下来。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Patient details, including demographic and clinical characteristics such as age at diagnosis, gender, tumor location (High, middle and low rectum), as well as preoperative carcinoembryonic antigen and CA19-9 levels, were retrieved and collected through the hospital's medical record system. The data will be anonymized by using the unique patient identification number (ID) assigned within the hospital system. Radiological and pathological results as well as treatment data will also be recorded.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-10 11:06:43